Madrigal Pharmaceuticals Inc.

MDGL | NASDAQ

Price Alert Chart Builder DCF Calculator

$432.00

+$1.64 (+0.38%)

Nov 2, 2026, 9:31 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.38%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

50.9

+1.5 pts

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Sector Rank #262/1028 (Top 25%)

Full Analysis

Key Statistics

Market Data

Market Cap $9.98B

1D Range

429.50 432.00

52W Range

412.35 602.83

Valuation (TTM)

PE -33.39

PB 18.99

EV/EBITDA -31.64

Valuation (NTM)

Forward PE 153.67

Forward PEG 0.73

Price Target $684.80

Cash Flow

FCF Yield -2.1%

SBC Adj. FCF Yield -3.0%

SBC Impact -46.4%

Margins

Gross Margin 91.5%

Operating Margin -25.1%

FCF Margin -16.1%

Growth (CAGR)

Revenue 3Y | 5Y 105.0% | 85.0%

Dil EPS 3Y | 5Y 36.9% | 6.0%

FCF 3Y | 5Y 38.6% | -1.4%

Returns

ROA -26.1%

ROE -56.6%

ROIC -37.0%

Financial Health

Net Cash

$496.93M

Current Ratio 3.20

Interest Coverage -10.24

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, ...

Sector Healthcare

Industry Biotechnology

Employees 915

IPO Date Feb 6, 2007

Website www.madrigalpharma.com

Fiscal Year January - December

Full Company Profile

Latest News

6 days ago · zacks.com

Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know

Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 days ago · globenewswire.com

Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH

Rezdiffra ® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatment persistence in clinical practice; largest dataset spans more than 12,000 patients Clinical abstracts further characterize the positive effects of Rezdiffra on noninvasive measures of treatment response, cardiovascular risk markers and patient-reported outcomes CONSHOHOCKEN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that new clinical and real-world evidence (RWE) evaluating Rezdiffra and its growing impact on patient care will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , taking place Nov. 5-9 in Denver.

13 days ago · globenewswire.com

Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026

CONSHOHOCKEN, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2026 financial results on Tuesday, November 3, 2026, prior to the open of the U.S. financial markets.

2 months ago · seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

2 months ago · fool.com

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

Madrigal's only commercial drug, Rezdiffra, continues to grow sales. Institutional investors hold more than 95% of the stock's float.

2 months ago · fool.com

Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off

MASH cirrhosis could significantly expand Rezdiffra's addressable market. Madrigal's developing pipeline could reduce its dependence on Rezdiffra.

3 months ago · globenewswire.com

Madrigal Appoints John C. Reed, M.D.

CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C.

3 months ago · seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

3 months ago · globenewswire.com

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT.